Newly Diagnosed Prostate cancer patients are needed for a diagnostic imaging research study

UVA Tracking #
HSR200196
Principal Investigator
Lale Kostakoglu Shields
Contact
Julio Torres III
Contact Phone
434.982.4110
Official Trial Title
A prospective, Phase 3, multi-center, single-arm, imaging study investigating the safety and diagnostic performance of rhPSMA-7.3 (18F) PET ligand in men with newly diagnosed prostate cancer
Study Description

The UVA Cancer Center is conducting a clinical diagnostic imaging research study for adults ages 18 and over with newly diagnosed prostate cancer. We want to learn more about the use of an experimental radiopharmaceutical agent used for PET imaging to help diagnose and look for the spread of prostate cancer. You may be eligible if you have recently been diagnosed with prostate cancer and have had no prior therapy.

Participation involves a 1-4 week Screening Period, study drug administration and PET scan imaging visit, and a safety visit within 1 to 3 days following study drug administration. During this study, you will need to come on site 3 times for about 4 hours each visit. Within 45 days of completing this study, you will follow a plan to treat your cancer through standard clinical care, as determined by your doctor. Study specific tests will be provided at no cost to you.

Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT04186819

Compensation

No Compensation